ejyceh.wordpress.com
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical Foundedin 1978, Biogen Idec is a globao leader in the discovery, development, manufacturing and commercializatiob of innovative therapies. Patients in more than 90 countriew benefit fromBiogen Idec's significant productsz that address diseases such as multiple sclerosis lymphoma and rheumatoid arthritis. In 2008, Biogejn Idec's total revenues grew 29 percent over 2007to $4.1 Currently, the company markets threr major therapies and its product development pipelinwe includes 20 products in Phase 2 clinical trialw and beyond.
Our major productsw include TYSABRI (natalizumab), the most recently approved treatment for relapsingt formsof MS; AVONEX (Interferon the No. 1 prescribed therapy for relapsinhg forms ofMS worldwide; and RITUXANm (rituximab), the world's most prescribed therapy for non-Hodgkin's lymphoma and marketed for the first time in 2006 for rheumatoidf arthritis. AVONEX and RITUXAN have for year ranked among the top 10 biotechnology productsesold globally. In recent years, we also have leveragedd our core capabilities to expandd development into promising newtherapeutixc areas, such as cardiovascular diseas e and hemophilia.
Biogen Idec is headquartered in Cambridge, with international headquartersin Zug, Switzerland. We have additional officese inthe U.S., Canada, Japan and throughout Europe. ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment